

AFFINIS Black Edition heavy body

Coltène/Whaledent AG

Version No: 3.3

Safety data sheet according to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758

Issue Date: **10/09/2024**Print Date: **19/11/2024**L.REACH.GB.EN

SECTION 1 Identification of the substance / mixture and of the company / undertaking

1.1. Product Identifier

Product name	AFFINIS Black Edition heavy body	
Chemical Name	Applicable	
Synonyms	Not Available	
Chemical formula	Not Applicable	
Other means of identification	Not Available	

1.2. Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses	Medical device, for dental use only Use according to manufacturer's directions.
Uses advised against	No specific uses advised against are identified.

1.3. Details of the manufacturer or supplier of the safety data sheet

Registered company name	Coltène/Whaledent AG
Address	Feldwiesenstrasse 20 Altstätten 9450 Switzerland
Telephone	+41 (71) 75 75 300
Fax	+41 (71) 75 75 301
Website	www.coltene.com
Email	msds@coltene.com

1.4. Emergency telephone number

Association / Organisation	CHEMWATCH EMERGENCY RESPONSE (24/7)
Emergency telephone number(s)	+44 20 3901 3542
Other emergency telephone number(s)	+44 808 164 9592

Once connected and if the message is not in your preferred language then please dial 01

SECTION 2 Hazards identification

2.1. Classification of the substance or mixture

Classified according to GB-CLP Regulation, UK SI 2019/720 and UK SI 2020/1567 ^[1]	Non hazardous
Legend:	1. Classified by Chemwatch; 2. Classification drawn from GB-CLP Regulation, UK SI 2019/720 and UK SI 2020/1567

2.2. Label elements

Hazard pictogram(s)	Not Applicable	
Signal word	Not Applicable	

Version No: **3.3** Page **2** of **16** Issue Date: **10/09/2024**

AFFINIS Black Edition heavy body

Print Date: 19/11/2024

Hazard statement(s)

Not Applicable

Supplementary statement(s)

EUH210

Safety data sheet available on request.

Precautionary statement(s) Prevention

Not Applicable

Precautionary statement(s) Response

Not Applicable

Precautionary statement(s) Storage

Not Applicable

Precautionary statement(s) Disposal

Not Applicable

Material contains cristobalite, Celite, Silanamine, 1,1,1-trimethyl-N- (trimethylsilyl)-, hydrolysis products with silica.

2.3. Other hazards

REACH - Art.57-59: The mixture does not contain Substances of Very High Concern (SVHC) at the SDS print date.

SECTION 3 Composition / information on ingredients

3.1.Substances

See 'Composition on ingredients' in Section 3.2

3.2.Mixtures

1. CAS No 2.EC No 3.Index No 4.REACH No	% [weight]	Name	Classified according to GB- CLP Regulation, UK SI 2019/720 and UK SI 2020/1567	SCL / M- Factor	Nanoform Particle Characteristics
1. 68855-54-9 2.272-489-0 3.Not Available 4.Not Available	<1	<u>Celite</u>	Specific Target Organ Toxicity - Repeated Exposure Category 2; H373 ^[1]	SCL: Not Available Acute M factor: Not Available Chronic M factor: Not Available	Not Available
1. 14464-46-1 2.238-455-4 3.Not Available 4.Not Available	30-40	<u>cristobalite</u>	Specific Target Organ Toxicity - Repeated Exposure Category 2; H373 [1]	SCL: Not Available Acute M factor: Not Available Chronic M factor: Not Available	Not Available
1. 128-37-0 2.204-881-4 3.Not Available 4.None	0.1	2,6-di-tert-butyl-4-methylphenol*	Hazardous to the Aquatic Environment Long-Term Hazard Category 1; H410 ^[1]	SCL: Not Available Acute M factor: Not Available Chronic M factor: Not Available	Not Available
1. 68909-20-6 2.Not Available 3.Not Available 4.Not Available	<1	Silanamine, 1,1,1-trimethyl-N- (trimethylsilyl)-, hydrolysis products with silica	Specific Target Organ Toxicity - Repeated Exposure Category 2; H373, EUH066 ^[1]	SCL: Not Available Acute M factor: Not Available Chronic M factor: Not Available	Not Available
Legend:	1. Classifie	ed by Chemwatch: 2. Classification d	rawn from GB-CLP Regulation, UK SI	2019/720 and UK S	I 2020/1567; 3.

Classification drawn from C&L; * EU IOELVs available; [e] Substance identified as having endocrine disrupting properties

Version No: **3.3** Page **3** of **16** Issue Date: **10/09/2024**

Print Date: 19/11/2024

AFFINIS Black Edition heavy body

SECTION 4 First aid measures

4.1. Description of first aid measures

Eye Contact	If this product comes in contact with the eyes:	
	Wash out immediately with fresh running water.	
	• Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally	
	lifting the upper and lower lids. • Seek medical attention without delay; if pain persists or recurs seek medical attention.	
	Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.	
	Nemoval of Contact lenses after an eye injury should only be undertaken by skilled personner.	
Skin Contact	If skin or hair contact occurs:	
	▶ Flush skin and hair with running water (and soap if available).	
	Seek medical attention in event of irritation.	
Inhalation	▶ If fumes, aerosols or combustion products are inhaled remove from contaminated area.	
	Other measures are usually unnecessary.	
	▶ Immediately give a glass of water.	
Ingestion	First aid is not generally required. If in doubt, contact a Poisons Information Centre or a doctor.	

4.2 Most important symptoms and effects, both acute and delayed

See Section 11

4.3. Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

SECTION 5 Firefighting measures

5.1. Extinguishing media

- ▶ There is no restriction on the type of extinguisher which may be used.
- Use extinguishing media suitable for surrounding area.

Fire Incompatibility None known.

5.2. Special hazards arising from the substrate or mixture

5.3. Advice for firefighters		
Fire Fighting	 Alert Fire Brigade and tell them location and nature of hazard. Wear breathing apparatus plus protective gloves in the event of a fire. Prevent, by any means available, spillage from entering drains or water courses. Use fire fighting procedures suitable for surrounding area. DO NOT approach containers suspected to be hot. Cool fire exposed containers with water spray from a protected location. If safe to do so, remove containers from path of fire. Equipment should be thoroughly decontaminated after use. 	
Fire/Explosion Hazard	 Non combustible. Not considered a significant fire risk, however containers may burn. May emit corrosive fumes. 	

SECTION 6 Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

See section 8

6.2. Environmental precautions

See section 12

6.3. Methods and material for containment and cleaning up

Minor Spills	 Clean up all spills immediately. Avoid contact with skin and eyes. Wear impervious gloves and safety goggles. Trowel up/scrape up. Place spilled material in clean, dry, sealed container. Flush spill area with water.
Major Spills	 Clear area of personnel and move upwind. Alert Fire Brigade and tell them location and nature of hazard. Wear full body protective clothing with breathing apparatus. Prevent, by all means available, spillage from entering drains or water courses. Consider evacuation (or protect in place). No smoking, naked lights or ignition sources.

Page 4 of 16 Issue Date: 10/09/2024 Version No: 3.3

Print Date: 19/11/2024 **AFFINIS Black Edition heavy body**

- Increase ventilation.
- Stop leak if safe to do so.
- ▶ Water spray or fog may be used to disperse / absorb vapour.
- Contain or absorb spill with sand, earth or vermiculite.
- ▶ Collect recoverable product into labelled containers for recycling.
- Collect solid residues and seal in labelled drums for disposal.
- Wash area and prevent runoff into drains.
- After clean up operations, decontaminate and launder all protective clothing and equipment before storing and re-using.
- If contamination of drains or waterways occurs, advise emergency services.

6.4. Reference to other sections

Personal Protective Equipment advice is contained in Section 8 of the SDS.

SECTION 7 Handling and storage

7.1. Precautions for safe handling

7.1. Frecautions for sale flatituting		
Safe handling	 Limit all unnecessary personal contact. Wear protective clothing when risk of exposure occurs. Use in a well-ventilated area. Avoid contact with incompatible materials. When handling, DO NOT eat, drink or smoke. Keep containers securely sealed when not in use. Avoid physical damage to containers. Always wash hands with soap and water after handling. Work clothes should be laundered separately. Use good occupational work practice. Observe manufacturer's storage and handling recommendations contained within this SDS. Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained. 	
Fire and explosion protection	See section 5	
Other information	 Store in original containers. Keep containers securely sealed. Store in a cool, dry, well-ventilated area. Store away from incompatible materials and foodstuff containers. Protect containers against physical damage and check regularly for leaks. Observe manufacturer's storage and handling recommendations contained within this SDS. 	

7.2. Conditions for safe storage, including any incompatibilities

Suitable container	Recommended storage temperature: 15 - 23 °C Polyethylene or polypropylene container. Packing as recommended by manufacturer. Check all containers are clearly labelled and free from leaks.	
Storage incompatibility	one known	
Hazard categories in accordance with Regulation (EC) No 2012/18/EU (Seveso III)	Not Available	
Qualifying quantity (tonnes) of dangerous substances as referred to in Article 3(10) for the application of	Not Available	

7.3. Specific end use(s)

See section 1.2

SECTION 8 Exposure controls / personal protection

8.1. Control parameters

Ingredient	DNELs Exposure Pattern Worker	PNECs Compartment
Celite	Inhalation 0.05 mg/m³ (Systemic, Chronic) Inhalation 0.00005 mg/m³ (Systemic, Chronic) * Oral 18.7 mg/kg bw/day (Systemic, Chronic) *	100 mg/L (STP)
2,6-di-tert-butyl-4- methylphenol*	Dermal 0.5 mg/kg bw/day (Systemic, Chronic) Inhalation 1.76 mg/m³ (Systemic, Chronic)	0.000199 mg/L (Water (Fresh)) 0.00199 mg/L (Water - Intermittent release)

 Version No: 3.3
 Page 5 of 16
 Issue Date: 10/09/2024

 Print Date: 19/11/2024
 Print Date: 19/11/2024

AFFINIS Black Edition heavy body

Ingredient	DNELs Exposure Pattern Worker	PNECs Compartment
	Dermal 0.25 mg/kg bw/day (Systemic, Chronic) * Inhalation 0.000435 mg/m³ (Systemic, Chronic) * Oral 0.25 mg/kg bw/day (Systemic, Chronic) *	0.00002 mg/L (Water (Marine)) 0.458 mg/kg sediment dw (Sediment (Fresh Water)) 0.046 mg/kg sediment dw (Sediment (Marine)) 0.054 mg/kg soil dw (Soil) 0.017 mg/L (STP) 16.67 mg/kg food (Oral)

^{*} Values for General Population

Occupational Exposure Limits (OEL)

INGREDIENT DATA

Source	Ingredient	Material name	TWA	STEL	Peak	Notes
UK Workplace Exposure Limits (WELs).	Celite	Silica, amorphous: inhalable dust	6 mg/m3	Not Available	Not Available	Not Available
UK Workplace Exposure Limits (WELs).	Celite	Silica, amorphous: respirable dust	2.4 mg/m3	Not Available	Not Available	Not Available
UK Workplace Exposure Limits (WELs).	cristobalite	Silica, respirable crystalline (respirable fraction)	0.1 mg/m3	Not Available	Not Available	Carc (where generated as a result of a work process)
UK Workplace Exposure Limits (WELs).	2,6-di-tert-butyl-4-methylphenol*	2,6-Di-tert-butyl-p- cresol	10 mg/m3	Not Available	Not Available	Not Available
UK Workplace Exposure Limits (WELs).	Silanamine, 1,1,1-trimethyl-N- (trimethylsilyl)-, hydrolysis products with silica	Silica, amorphous: inhalable dust	6 mg/m3	Not Available	Not Available	Not Available
UK Workplace Exposure Limits (WELs).	Silanamine, 1,1,1-trimethyl-N- (trimethylsilyl)-, hydrolysis products with silica	Silica, amorphous: respirable dust	2.4 mg/m3	Not Available	Not Available	Not Available

Ingredient	Original IDLH	Revised IDLH
Celite	Not Available	Not Available
cristobalite	Not Available	Not Available
2,6-di-tert-butyl-4- methylphenol*	Not Available	Not Available
Silanamine, 1,1,1-trimethyl- N- (trimethylsilyl)-, hydrolysis products with silica	Not Available	Not Available

MATERIAL DATA

Sensory irritants are chemicals that produce temporary and undesirable side-effects on the eyes, nose or throat. Historically occupational exposure standards for these irritants have been based on observation of workers' responses to various airborne concentrations. Present day expectations require that nearly every individual should be protected against even minor sensory irritation and exposure standards are established using uncertainty factors or safety factors of 5 to 10 or more. On occasion animal no-observable-effect-levels (NOEL) are used to determine these limits where human results are unavailable. An additional approach, typically used by the TLV committee (USA) in determining respiratory standards for this group of chemicals, has been to assign ceiling values (TLV C) to rapidly acting irritants and to assign short-term exposure limits (TLV STELs) when the weight of evidence from irritation, bioaccumulation and other endpoints combine to warrant such a limit. In contrast the MAK Commission (Germany) uses a five-category system based on intensive odour, local irritation, and elimination half-life. However this system is being replaced to be consistent with the European Union (EU) Scientific Committee for Occupational Exposure Limits (SCOEL); this is more closely allied to that of the USA.

OSHA (USA) concluded that exposure to sensory irritants can:

- cause inflammation
- cause increased susceptibility to other irritants and infectious agents
- lead to permanent injury or dysfunction
- permit greater absorption of hazardous substances and
- acclimate the worker to the irritant warning properties of these substances thus increasing the risk of overexposure.

8.2. Exposure controls

8.2.1. Appropriate engineering controls

Engineering controls are used to remove a hazard or place a barrier between the worker and the hazard. Well-designed engineering controls can be highly effective in protecting workers and will typically be independent of worker interactions to provide this high level of protection.

The basic types of engineering controls are:

Process controls which involve changing the way a job activity or process is done to reduce the risk.

Enclosure and/or isolation of emission source which keeps a selected hazard "physically" away from the worker and ventilation that strategically "adds" and "removes" air in the work environment. Ventilation can remove or dilute an air contaminant if designed properly. The design of a ventilation system must match the particular process and chemical or contaminant in use. Employers may need to use multiple types of controls to prevent employee overexposure.

Version No: **3.3** Page **6** of **16** Issue Date: **10/09/2024**

AFFINIS Black Edition heavy body

► Employees exposed to confirmed human carcinogens should be authorized to do so by the employer, and work in a

▶ Work should be undertaken in an isolated system such as a "glove-box" . Employees should wash their hands and arms upon completion of the assigned task and before engaging in other activities not associated with the isolated system.

Print Date: 19/11/2024

- Within regulated areas, the carcinogen should be stored in sealed containers, or enclosed in a closed system, including piping systems, with any sample ports or openings closed while the carcinogens are contained within.
- Open-vessel systems are prohibited.
- Each operation should be provided with continuous local exhaust ventilation so that air movement is always from ordinary work areas to the operation.
- Exhaust air should not be discharged to regulated areas, non-regulated areas or the external environment unless decontaminated. Clean make-up air should be introduced in sufficient volume to maintain correct operation of the local exhaust system.
- For maintenance and decontamination activities, authorized employees entering the area should be provided with and required to wear clean, impervious garments, including gloves, boots and continuous-air supplied hood. Prior to removing protective garments the employee should undergo decontamination and be required to shower upon removal of the garments and hood.
- Except for outdoor systems, regulated areas should be maintained under negative pressure (with respect to non-regulated areas).
- Local exhaust ventilation requires make-up air be supplied in equal volumes to replaced air.
- Laboratory hoods must be designed and maintained so as to draw air inward at an average linear face velocity of 0.76 m/sec with a minimum of 0.64 m/sec. Design and construction of the fume hood requires that insertion of any portion of the employees body, other than hands and arms, be disallowed.

8.2.2. Individual protection measures, such as personal protective equipment









Eye and face protection

Safety glasses with side shields.

- ► Chemical goggles. [AS/NZS 1337.1, EN166 or national equivalent]
- Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59].

Skin protection

See Hand protection below

Hands/feet protection

- ▶ Wear chemical protective gloves, e.g. PVC.
- ▶ Wear safety footwear or safety gumboots, e.g. Rubber

Body protection

See Other protection below

Other protection

- Overalls.
- ► P.V.C apron.
- Barrier cream.
- Skin cleansing cream.
- ▶ Eye wash unit.

Respiratory protection

Type A-P Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

Where the concentration of gas/particulates in the breathing zone, approaches or exceeds the "Exposure Standard" (or ES), respiratory protection is required. Degree of protection varies with both face-piece and Class of filter; the nature of protection varies with Type of filter.

Required Minimum Protection Factor	Half-Face Respirator	Full-Face Respirator	Powered Air Respirator
up to 10 x ES	A-AUS P2	-	A-PAPR-AUS / Class 1 P2
up to 50 x ES	-	A-AUS / Class 1 P2	-
up to 100 x ES	-	A-2 P2	A-PAPR-2 P2 ^

^ - Full-face

A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

8.2.3. Environmental exposure controls

See section 12

SECTION 9 Physical and chemical properties

9.1. Information on basic physical and chemical properties

Appearance

Dark

AFFINIS Black Edition heavy body

Physical state	Free-flowing Paste	Relative density (Water = 1)	Not Available
Odour	Not Available	Partition coefficient n- octanol / water	Not Available
Odour threshold	Not Available	Auto-ignition temperature (°C)	Not Available
pH (as supplied)	Not Available	Decomposition temperature (°C)	Not Available
Melting point / freezing point (°C)	Not Available	Viscosity (cSt)	Not Available
Initial boiling point and boiling range (°C)	Not Available	Molecular weight (g/mol)	Not Available
Flash point (°C)	Not Available	Taste	Not Available
Evaporation rate	Not Available	Explosive properties	Not Available
Flammability	Not Available	Oxidising properties	Not Available
Upper Explosive Limit (%)	Not Available	Surface Tension (dyn/cm or mN/m)	Not Available
Lower Explosive Limit (%)	Not Available	Volatile Component (%vol)	Not Available
Vapour pressure (kPa)	Not Available	Gas group	Not Available
Solubility in water	Immiscible	pH as a solution (1%)	Not Available
Vapour density (Air = 1)	Not Available	VOC g/L	Not Available
Heat of Combustion (kJ/g)	Not Available	Ignition Distance (cm)	Not Available
Flame Height (cm)	Not Available	Flame Duration (s)	Not Available
Enclosed Space Ignition Time Equivalent (s/m3)	Not Available	Enclosed Space Ignition Deflagration Density (g/m3)	Not Available
Nanoform Solubility	Not Available	Nanoform Particle Characteristics	Not Available
Particle Size	Not Available		

9.2. Other information

Not Available

SECTION 10 Stability and reactivity

10.1.Reactivity	See section 7.2
10.2. Chemical stability	Product is considered stable and hazardous polymerisation will not occur.
10.3. Possibility of hazardous reactions	See section 7.2
10.4. Conditions to avoid	See section 7.2
10.5. Incompatible materials	See section 7.2
10.6. Hazardous decomposition products	See section 5.3

SECTION 11 Toxicological information

11.1. Information on toxicological effects

Inhaled	
Ingestion	
Skin Contact	
Eye	
Chronic	

AFFINIS Black Edition	TOXICITY	IRRITATION
heavy body	Not Available	Not Available
Celite	TOXICITY	IRRITATION
	Inhalation (Rat) LC50: >2.6 mg/l4h ^[1]	Eye: no adverse effect observed (not irritating) ^[1]

Version No: 3.3 Page 8 of 16 Issue Date: 10/09/2024
Print Date: 19/11/2024

AFFINIS Black Edition heavy body

	Oral (Rat) LD50: >2000 mg/kg ^[1]	Skin: no adverse effect observed (not irritating) ^[1]
	TOXICITY	IRRITATION
cristobalite	Not Available	Not Available
	TOXICITY	IRRITATION
2,6-di-tert-butyl-4- methylphenol*	Dermal (rabbit) LD50: >2000 mg/kg *[2]	Eye (Rodent - rabbit): 100mg/24H - Moderate
	Oral (Rat) LD50: >2000 mg/kg *[2]	Eye: no adverse effect observed (not irritating) ^[1]
	Oral (Rat) LD50: 890 mg/kg ^[2]	Skin (Human): 500mg/48H - Mild
	Oral (woman) TDLo: 80 mg/kg ^[2]	Skin (Rodent - rabbit): 500mg/48H - Moderate
		Skin: no adverse effect observed (not irritating) ^[1]
Silanamine, 1,1,1-trimethyl-	TOXICITY	IRRITATION
N- (trimethylsilyl)-, hydrolysis products with silica	Oral (Rat) LD50: >5000 mg/kg ^[2]	Not Available
Legend:	,	ostances - Acute toxicity 2. Value obtained from manufacturer's SDS. CS - Register of Toxic Effect of chemical Substances

For silica amorphous:

Derived No Adverse Effects Level (NOAEL) in the range of 1000 mg/kg/d.

In humans, synthetic amorphous silica (SAS) is essentially non-toxic by mouth, skin or eyes, and by inhalation. Epidemiology studies show little evidence of adverse health effects due to SAS. Repeated exposure (without personal protection) may cause mechanical irritation of the eye and drying/cracking of the skin.

When experimental animals inhale synthetic amorphous silica (SAS) dust, it dissolves in the lung fluid and is rapidly eliminated. If swallowed, the vast majority of SAS is excreted in the faeces and there is little accumulation in the body. Following absorption across the gut, SAS is eliminated via urine without modification in animals and humans. SAS is not expected to be broken down (metabolised) in mammals.

After ingestion, there is limited accumulation of SAS in body tissues and rapid elimination occurs. Intestinal absorption has not been calculated, but appears to be insignificant in animals and humans. SASs injected subcutaneously are subjected to rapid dissolution and removal. There is no indication of metabolism of SAS in animals or humans based on chemical structure and available data. In contrast to crystalline silica, SAS is soluble in physiological media and the soluble chemical species that are formed are eliminated via the urinary tract without modification.

Both the mammalian and environmental toxicology of SASs are significantly influenced by the physical and chemical properties, particularly those of solubility and particle size. SAS has no acute intrinsic toxicity by inhalation. Adverse effects, including suffocation, that have been reported were caused by the presence of high numbers of respirable particles generated to meet the required test atmosphere. These results are not representative of exposure to commercial SASs and should not be used for human risk assessment. Though repeated exposure of the skin may cause dryness and cracking, SAS is not a skin or eye irritant, and it is not a sensitiser.

Celite

Repeated-dose and chronic toxicity studies confirm the absence of toxicity when SAS is swallowed or upon skin contact. Long-term inhalation of SAS caused some adverse effects in animals (increases in lung inflammation, cell injury and lung collagen content), all of which subsided after exposure.

Numerous repeated-dose, subchronic and chronic inhalation toxicity studies have been conducted with SAS in a number of species, at airborne concentrations ranging from 0.5 mg/m3 to 150 mg/m3. Lowest-observed adverse effect levels (LOAELs) were typically in the range of 1 to 50 mg/m3. When available, the no-observed adverse effect levels (NOAELs) were between 0.5 and 10 mg/m3. The difference in values may be explained by different particle size, and therefore the number of particles administered per unit dose. In general, as particle size decreases so does the NOAEL/LOAEL.

Neither inhalation nor oral administration caused neoplasms (tumours). SAS is not mutagenic in vitro. No genotoxicity was detected in in vivo assays. SAS does not impair development of the foetus. Fertility was not specifically studied, but the reproductive organs in long-term studies were not affected.

For Synthetic Amorphous Silica (SAS)

Repeated dose toxicity

Oral (rat), 2 weeks to 6 months, no significant treatment-related adverse effects at doses of up to 8% silica in the diet. Inhalation (rat), 13 weeks, Lowest Observed Effect Level (LOEL) =1.3 mg/m3 based on mild reversible effects in the lungs. Inhalation (rat), 90 days, LOEL = 1 mg/m3 based on reversible effects in the lungs and effects in the nasal cavity. For silane treated synthetic amorphous silica:

Repeated dose toxicity: oral (rat), 28-d, diet, no significant treatment-related adverse effects at the doses tested.

There is no evidence of cancer or other long-term respiratory health effects (for example, silicosis) in workers employed in the manufacture of SAS. Respiratory symptoms in SAS workers have been shown to correlate with smoking but not with SAS exposure, while serial pulmonary function values and chest radiographs are not adversely affected by long-term exposure to SAS.

cristobalite

Inhalation (human) TCLo: 16 mppcf*/8H/17.9y-I * Millions of particles per cubic foot

WARNING: For inhalation exposure ONLY: This substance has been classified by the IARC as Group 1: CARCINOGENIC TO

The International Agency for Research on Cancer (IARC) has classified occupational exposures to **respirable** (<5 um) crystalline silica as being carcinogenic to humans. This classification is based on what IARC considered sufficient evidence from epidemiological studies of humans for the carcinogenicity of inhaled silica in the forms of quartz and cristobalite. Crystalline silica is also known to cause silicosis, a non-cancerous lung disease.

Intermittent exposure produces; focal fibrosis, (pneumoconiosis), cough, dyspnoea, liver tumours.

Version No: **3.3** Page **9** of **16** Issue Date: **10/09/2024**

AFFINIS Black Edition heavy body

Print Date: 19/11/2024

* Millions of particles per cubic foot (based on impinger samples counted by light field techniques).

NOTE: the physical nature of quartz in the product determines whether it is likely to present a chronic health problem. To be a hazard the material must enter the breathing zone as respirable particles.

2,6-di-tert-butyl-4methylphenol*

* Degussa SDS Effects such as behavioral changes, reduction in body weight gain, and decrement in body weight have been observed after long-term administration of BHT to mice and rats. Toxic effects may be attributed more to BHT metabolites than to their parent compound, only a few studies have focused on their carcinogenicity and toxicity, and not only on that of BHT. The metabolite BHT-QM (syn: 2,6-di-tert-butyl-1,4-methylene-2,5-cyclohexadien-1-one, CAS RN: 2607-52-5) is a very reactive compound which is considered to play a significant role in hepatoxicity, pneumotoxicity, and skin tumor promotion in mice. In addition, it was reported that another quinone derivative, BHT-OH(t)QM (syn 2-tert-butyl-6-(2-hydroxy-tert-butyl-4-methylene-2,5cyclohexadien-1-one, CAS RN: 124755-19-7), is chemically more reactive than BHT-QM, and it has been recognized as the principal metabolite responsible for lung tumor promotion activity of BHT in mice. BHT has been reported to exert prooxidant effects under certain conditions. Thus, when BHT was added in excess to a wheat seedling medium in aerobic conditions, an enhancement of the generation rate of superoxide anion was observed. This is a reactive particle that may damage cellular structures at high concentrations In addition, an increase in hepatic microsomal lipid peroxidation was observed in rats fed with diets containing 0.2% of BHT for 30 days. Due to this ability of BHT to exert prooxidant effects at high concentrations, it has been used to induce experimental models of oxidative stress in several animals and fungi in order to study the protective effects of other compounds. Quinone methide derivatives form adducts with several proteins, including enzymes that protect cells from oxidative stress; this prooxidant state can also lead to cell oxidative damage. It must be noted that relationships between chronic oxidative stress and tumor promotion are well known Some authors have reported that at high aeration rate, BHT can react with molecular oxygen rather than with the reactive oxygen species present, yielding BHT-phenoxyl radical and superoxide anion. In addition, the phenolic radical itself may undergo redox recycling which can be a critical factor depending on the reductant involved However, it has to be noted that BHT-phenoxyl radical has been reported to be relatively stable. Furthermore, the potential reactivity of BHT-derived metabolites should be taken into account; some studies reported that not only BHT but also its metabolites, such as BHT-Q and BHT-QM, can act as prooxidant. As BHT undergoes several reactions during biotransformation, a large number of intermediate metabolites have been identified. However, their nature and concentration depend on the environmental conditions and on the animal species. Although the changes undergone by BHT during in vivo digestion processes have not been studied, after submission of a fluid deep-frying fat containing BHT and BHT-QM to an in vitro gastrointestinal digestion model, both these were detected in the digested samples. These results indicate that BHT and its toxic metabolite could remain bioaccessible for intestinal absorption. Studies concerning BHT metabolism have shown that, unlike other synthetic antioxidants, BHT is a potent inducer of the microsomal monooxygenase system and its major route of degradation is oxidation catalyzed by cytochrome P450. Studies have reported potential toxicity derived from the ingestion or administration of BHT. As for acute oral toxicity, although this is considered low in animals, it must be noted that 2 clinical cases were reported in patients who suffered acute neurotoxicity and gastritis after ingesting a high dose of BHT (4 and 80 g without medical prescription) to cure recurrent genital herpes. Regarding short-term subchronic toxicity studies, it has been reported that BHT causes dose-related increase in the incidence and severity of toxic nephrosis in mice, nephrotoxicity and pneumotoxicity in rats, and in chicken a marked congestion of the liver and kidney, as well as diffuse enlargement of the liver with rounded borders and rupture with hemorrhaging . It has to be noted that the EFSA Panel (2012) pointed out certain inconsistencies in the findings obtained from the short-term and subchronic toxicity studies. Several genotoxicity studies on BHT concluded that BHT does not represent a genotoxic risk, because most of the studies carried out to that date had shown BHT was not able to induce mutations or to damage deoxyribonucleic acid (DNA). Nevertheless, it must be mentioned that other studies reported contrary results. The effect of BHT and 7 of its metabolites on in vitro DNA cleavage was studied and the metabolites BHT-Q (syn: 2,6-di-tert-butyl-2,5cyclohexadiene-1,4-dione, CAS RN: 719-22-2), BHT-CHO (syn: 3,5-di-tert-butyl-4-hydroxybenzaldehyde, CAS RN: 1620-98-0 and BHT-OOH (syn: 2,6-di-tert-butyl-4-methyl-4-hydroperoxy-2,5-cyclohexadien-1-one, CAS RN: 6485-57-0) were able to cleave DNA.. The Panel on Food Additives and Nutrient Sources Added to Food of the European Food Safety Authority (EFSA) recognized that these positive genotoxicity results may be due to the prooxidative chemistry of BHT, which gives rise to reactive metabolites. Some studies addressed the carcinogenicity and chronic toxicity of BHT and its metabolites in rodents with contradictory results. Thus, mice-fed dietary BHT for a year developed marked hyperplasia of the hepatic bile ducts with an associated subacute cholangitis Moreover, after 104 wk of administration of BHT, the formation of hepatocellular tumors in male mice was observed. After 10 months of feeding mice with a diet containing different amounts of BHT, an increased incidence of liver tumors in male, but not female, animals was also reported . However, in a similar study no evidence of the carcinogenicity of BHT administered to mice was observed. Studies performed in rats also reported dose-related increases in hepatocellular adenomas and carcinomas; nevertheless, other studies carried out with rats showed no consistent carcinogenic effects. Several studies have demonstrated the potential of BHT to act either as a tumor promotor or as a tumor suppressor, modulating the carcinogenicity of some well-known carcinogens. Barbara Nieva-Echevarria etal: Comprehensive reviews in Food Science and Food Safety, Vol 14, Dec 2014 https://onlinelibrary.wiley.com/doi/10.1111/1541-4337.12121/pdf

Exposure to the material may result in a possible risk of irreversible effects. The material may produce mutagenic effects in man. This concern is raised, generally, on the basis of

appropriate studies using mammalian somatic cells in vivo. Such findings are often supported by positive results from in vitro mutagenicity studies.

The following information refers to contact allergens as a group and may not be specific to this product.

Contact allergies quickly manifest themselves as contact eczema, more rarely as urticaria or Quincke's oedema. The pathogenesis of contact eczema involves a cell-mediated (T lymphocytes) immune reaction of the delayed type. Other allergic skin reactions, e.g. contact urticaria, involve antibody-mediated immune reactions. The significance of the contact allergen is not simply determined by its sensitisation potential: the distribution of the substance and the opportunities for contact with it are equally important. A weakly sensitising substance which is widely distributed can be a more important allergen than one with stronger sensitising potential with which few individuals come into contact. From a clinical point of view, substances are noteworthy if they produce an allergic test reaction in more than 1% of the persons tested.

Asthma-like symptoms may continue for months or even years after exposure to the material ends. This may be due to a non-allergic condition known as reactive airways dysfunction syndrome (RADS) which can occur after exposure to high levels of highly irritating compound. Main criteria for diagnosing RADS include the absence of previous airways disease in a non-atopic individual, with sudden onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. Other criteria for diagnosis of RADS include a reversible airflow pattern on lung function tests, moderate to severe bronchial hyperreactivity on methacholine challenge testing, and the lack of minimal lymphocytic inflammation, without eosinophilia. RADS (or asthma) following an irritating inhalation is an infrequent disorder with rates related to the concentration of and duration of exposure to the irritating substance. On the other hand, industrial bronchitis is a disorder that occurs as a result

Version No: **3.3** Page **10** of **16** Issue Date: **10/09/2024**

AFFINIS Black Edition heavy body

Print Date: 19/11/2024

of exposure due to high concentrations of irritating substance (often particles) and is completely reversible after exposure ceases. The disorder is characterized by difficulty breathing, cough and mucus production. for bridged alkyl phenols:

Acute toxicity: Acute oral and dermal toxicity data are available for all but two of the substances in the group. The data show that acute toxicity of these substances is low. The testing for acute toxicity spans five decades

Repeat dose toxicity: Repeat dose studies on the members of this category include both subchronic and chronic exposures. The liver is identified as the target organ in rats for all of the substances tested. NOAEL s or NOEL s in rats for 13- week studies ranged from 100 ppm (approximately 5 mg/kg/day) to 500 ppm (approximately 25 mg/kg/day) while NOAEL s or NOEL s in rats for chronic studies were the same, 25 mg/kg/day (500 ppm).

Reproductive toxicity: Evaluation of effects on reproduction for the bridged alkyl phenols is supplemented by histopathological data on male and female reproductive organs in repeated dose studies. The data on the effects of bridged alkyl phenols on reproduction and reproductive organs span the range of structures and molecular weights. While not all of the data for reproductive effects are from reproduction studies, microscopic evaluations of reproductive organs along with other short-term tests for reproductive effects provide adequate data to evaluate the effects of these bridged alkyl phenols on reproduction It can be concluded that reproductive toxicity is low.

Typically a two-year chronic feeding study provides data for 4,4'-thiobis-6-(t-butyl-m-cresol) (96-69-5). No adverse effects were noted on reproductive organs

Genotoxicity: Data from bacterial reverse mutation assays and in vitro and in vivo chromosome aberration studies were reviewed. Adequate bacterial gene mutation assays have been conducted with all of the category chemicals except two. Chromosome aberration studies, in vitro and/or in vivo, are available for all but two substances. The mutagenicity data span the range of structures and molecular weights and data can be bridged from other members of the group to meet any outstanding requirements. The weight of evidence for mutagenic potential for this category indicates these substances are not mutagenic. **Carcinogenicity:** The mutagenicity data combined with the animal data plus the long historical use of BHT (128-37-0) indicate that the chemicals in this class are not expected to exhibit any significant potential to cause cancer. The weight of the evidence indicates that these chemicals are not genotoxic.

The Bridged Alkyl Phenols Category consists of a group of chemicals in which two molecules of mono or di-substituted alkyl (C1, C4, and/or C9) phenols are "bridged" or linked by a single atom (carbon or sulfur). The carbon atom linking the alkyl phenol groups contains hydrogen, propyl, or methyl substitutions. CAS No. 128-37-0 (BHT) is included in this category for data purposes because it is an alkyl phenol with a single carbon group such as the ones that link the phenol groups

ferroptosis inhibitors are currently being treated systemically rather than specifically, which may have multiple side effects. For example, Desferoxamin (DFO), an iron chelating agent, is known to have a short half-life, need long-term subcutaneous infusions, and provoke ototoxicity and neurotoxicity. Deferasirox (DFX), an iron chelator, is associated with gastrointestinal and renal toxicity.

The substance is classified by IARC as Group 3:

NOT classifiable as to its carcinogenicity to humans.

Evidence of carcinogenicity may be inadequate or limited in animal testing.

The material may cause skin irritation after prolonged or repeated exposure and may produce a contact dermatitis (nonallergic). This form of dermatitis is often characterised by skin redness (erythema) and swelling the epidermis. Histologically there may be intercellular oedema of the spongy layer (spongiosis) and intracellular oedema of the epidermis.

For hindered phenols:

Available data shows that acute toxicity of these substances is low.

Mutagenicity. Data from bacterial reverse mutation assays and *in vitro* and *in vivo* chromosome aberration studies were reviewed. All assays, with and without metabolic activation, were negative. The weight of evidence for mutagenic potential for this category indicates these substances are not mutagenic.

In Vitro Chromosome Aberration Studies. In vitro chromosome aberration studies are available for several members All except 2,6-di-tert-butyl-p-cresol were negative

In Vivo Chromosome Aberration Studies. In vivo studies evaluating chromosome damage are available for six of the hindered phenols. All in vivo evaluations were negative.

Repeated Dose Toxicity. Repeated dose toxicity data of approximately three months (90-day, 12- and 13-week) are available for some of the substances in this group. The liver was the target organ in rats for almost all of the substances with subchronic toxicity data in that species. Other target organs included thyroid and kidney and mesenteric lymph nodes. NOAELs in rats ranged from 100 ppm (approximately 5 mg/kg/day) to 10,000 ppm (500 mg/kg/day)

Carcinogenicity: Data is available for 2,6-di-tert-butyl-p-cresol (128-37-0); and 4,4'-thiobis-6-(t-butyl-m-cresol) (96-69-5). Liver adenomas were reported for 2,6-di-tert-butyl-p-cresol (128-37-0) and a NOAEL was established for the study at 25 mg/kg/day. 4,4'-Thiobis-6-(t-butyl-m-cresol) (96-69-5) was not carcinogenic in rats or mice, but the kidney was identified as a target organ in female rats

Acute Toxicity	×	Carcinogenicity	×
Skin Irritation/Corrosion	×	Reproductivity	×
Serious Eye Damage/Irritation	×	STOT - Single Exposure	×
Respiratory or Skin sensitisation	×	STOT - Repeated Exposure	×
Mutagenicity	×	Aspiration Hazard	×

Legend: X − Data either not available or does not fill the criteria for classification

Data available to make classification

11.2 Information on other hazards

11.2.1. Endocrine disrupting properties

No evidence of endocrine disrupting properties were found in the current literature.

Version No: 3.3 Page 11 of 16 Issue Date: 10/09/2024 Print Date: 19/11/2024

AFFINIS Black Edition heavy body

See Section 11.1

SECTION 12 Ecological information

12.1. Toxicity

AFFINIS Black Edition heavy body	Endpoint	Test Duration (hr)	Species	Value	Source
	Not Available	Not Available	Not Available	Not Available	Not Available
	Endpoint	Test Duration (hr)	Species	Value	Source
Celite	Not Available	Not Available	Not Available	Not Available	Not Available
cristobalite	Endpoint	Test Duration (hr)	Species	Value	Source
	Not Available	Not Available	Not Available	Not Available	Not Available
	Endpoint	Test Duration (hr)	Species	Value	Source
	EC50	96h	Algae or other aquatic plants	0.758mg/l	2
	BCF	1344h	Fish	220-2800	7
2,6-di-tert-butyl-4-	EC50	72h	Algae or other aquatic plants	>0.42mg/l	1
methylphenol*	EC0(ECx)	48h	Crustacea	>=0.31mg/l	1
	EC50	48h	Crustacea	>0.17mg/l	2
	ErC50	72h	Algae or other aquatic plants	>0.42mg/l	1
	LC50	96h	Fish	0.199mg/l	2
Silanamine, 1,1,1-trimethyl-	Endpoint	Test Duration (hr)	Species	Value	Source
N- (trimethylsilyl)-, hydrolysis products with silica	Not Available	Not Available	Not Available	Not Available	Not Available
Legend:	Extracted from 1. IUCLID Toxicity Data 2. Europe ECHA Registered Substances - Ecotoxicological Information - Aquatic To. 4. US EPA, Ecotox database - Aquatic Toxicity Data 5. ECETOC Aquatic Hazard Assessment Data 6. NITE (Japan) - Bioconcentration Data 7. METI (Japan) - Bioconcentration Data 8. Vendor Data				

12.2. Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
2,6-di-tert-butyl-4- methylphenol*	HIGH	HIGH

12.3. Bioaccumulative potential

Ingredient	Bioaccumulation
2,6-di-tert-butyl-4- methylphenol*	HIGH (BCF = 2500)

12.4. Mobility in soil

Ingredient	Mobility
2,6-di-tert-butyl-4- methylphenol*	LOW (Log KOC = 23030)

12.5. Results of PBT and vPvB assessment

	P	В	Т	
Relevant available data	Not Available	Not Available	Not Available	
PBT	×	×	×	
vPvB	×	×	×	
PBT Criteria fulfilled?	No			
vPvB	No			

12.6. Endocrine disrupting properties

AFFINIS Black Edition heavy body

No evidence of endocrine disrupting properties were found in the current literature.

12.7. Other adverse effects

No evidence of ozone depleting properties were found in the current literature.

SECTION 13 Disposal considerations

13.1. Waste treatment methods

Product / Packaging disposal Dispose of waste according to applicable legislation. Special country-specific regulations may apply. Can be with household waste in compliance with official regulations in contact with approved waste disposal comparation authorities in charge. (Only dispose of completely emptied packages.)	
Waste treatment options	Not Available
Sewage disposal options	Not Available

SECTION 14 Transport information

Labels Required

Marine Pollutant	NO
HAZCHEM	Not Applicable

Land transport (ADR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

14.1. UN number or ID number	Not Applicable	Not Applicable		
14.2. UN proper shipping name	Not Applicable			
14.3. Transport hazard	Class	Not Appli	cable	
class(es)	Subsidiary Hazard	Not Appli	cable	
14.4. Packing group	Not Applicable	Not Applicable		
14.5. Environmental hazard	Not Applicable			
	Hazard identification	n (Kemler)	Not Applicable	
	Classification code		Not Applicable	
14.6. Special precautions	Hazard Label		Not Applicable	
for user	Special provisions		Not Applicable	
	Limited quantity		Not Applicable	
	Tunnel Restriction C	ode	Not Applicable	

Air transport (ICAO-IATA / DGR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

14.1. UN number	Not Applicable			
14.2. UN proper shipping name	Not Applicable			
	ICAO/IATA Class	Not Applicable		
14.3. Transport hazard class(es)	ICAO / IATA Subsidiary Hazard	Not Applicable		
ciass(cs)	ERG Code	Not Applicable		
14.4. Packing group	Not Applicable	Not Applicable		
14.5. Environmental hazard	Not Applicable			
	Special provisions		Not Applicable	
	Cargo Only Packing Instructions	Not Applicable		
14.6. Special precautions for user	Cargo Only Maximum Qty / Pack	Not Applicable		
	Passenger and Cargo Packing In	Not Applicable		
	Passenger and Cargo Maximum Qty / Pack		Not Applicable	
	Passenger and Cargo Limited Quantity Packing Instructions		Not Applicable	
	Passenger and Cargo Limited Ma	aximum Qty / Pack	Not Applicable	

Page 13 of 16 Issue Date: 10/09/2024 Version No: 3.3 Print Date: 19/11/2024

AFFINIS Black Edition heavy body

Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

	1				
14.1. UN number	Not Applicable				
14.2. UN proper shipping name	Not Applicable	Not Applicable			
14.3. Transport hazard	IMDG Class	Not Applicable			
class(es)	IMDG Subsidiary Ha	azard Not Applicable			
14.4. Packing group	Not Applicable	Not Applicable			
14.5 Environmental hazard	Not Applicable				
	EMS Number	Not Applicable			
14.6. Special precautions for user	Special provisions	Not Applicable			
	Limited Quantities	Not Applicable			
	Limited Quantities	Not Applicable			

Inland waterways transport (ADN): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

14.1. UN number	Not Applicable				
14.2. UN proper shipping name	Not Applicable				
14.3. Transport hazard class(es)	Not Applicable Not Applicable				
14.4. Packing group	Not Applicable				
14.5. Environmental hazard	Not Applicable				
	Classification code Not Applicable				
14.6. Special precautions		Not Applicable			
for user		Not Applicable			
	Equipment required	Not Applicable			
	Fire cones number	Not Applicable			

14.7.1. Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

14.7.2. Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

Product name	Group
Celite	Not Available
cristobalite	Not Available
2,6-di-tert-butyl-4- methylphenol*	Not Available
Silanamine, 1,1,1-trimethyl- N- (trimethylsilyl)-, hydrolysis products with silica	Not Available

14.7.3. Transport in bulk in accordance with the IGC Code

Product name	Ship Type
Celite	Not Available
cristobalite	Not Available
2,6-di-tert-butyl-4- methylphenol*	Not Available
Silanamine, 1,1,1-trimethyl- N- (trimethylsilyl)-, hydrolysis products with silica	Not Available

SECTION 15 Regulatory information

15.1. Safety, health and environmental regulations / legislation specific for the substance or mixture

Version No: 3.3 Page 14 of 16 Issue Date: 10/09/2024

AFFINIS Black Edition heavy body

Print Date: 19/11/2024

International WHO List of Proposed Occupational Exposure Limit (OEL) Values for Manufactured Nanomaterials (MNMS)

UK Workplace Exposure Limits (WELs).

cristobalite is found on the following regulatory lists

Chemical Footprint Project - Chemicals of High Concern List

International WHO List of Proposed Occupational Exposure Limit (OEL) Values for Manufactured Nanomaterials (MNMS)

UK Workplace Exposure Limits (WELs).

2,6-di-tert-butyl-4-methylphenol* is found on the following regulatory lists

International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs - Not Classified as Carcinogenic

International WHO List of Proposed Occupational Exposure Limit (OEL) Values for Manufactured Nanomaterials (MNMS)

UK Workplace Exposure Limits (WELs).

Silanamine, 1,1,1-trimethyl-N- (trimethylsilyl)-, hydrolysis products with silica is found on the following regulatory lists

Great Britain GB Biocidal Active Substances

Great Britain GB mandatory classification and labelling (GB MCL) technical reports

Great Britain GB mandatory classification and labelling list (GB MCL)

International WHO List of Proposed Occupational Exposure Limit (OEL) Values for Manufactured Nanomaterials (MNMS)

UK Workplace Exposure Limits (WELs).

Additional Regulatory Information

Not Applicable

This safety data sheet is in compliance with the following EU legislation and its adaptations - as far as applicable -: Directives 98/24/EC, - 92/85/EEC, - 94/33/EC,

- 2008/98/EC, - 2010/75/EU; Commission Regulation (EU) 2020/878; Regulation (EC) No 1272/2008 as updated through ATPs.

Information according to 2012/18/EU (Seveso III):

Seveso Category Not Available

15.2. Chemical safety assessment

No Chemical Safety Assessment has been carried out for this substance/mixture by the supplier.

National Inventory Status

National Inventory	Status		
Australia - AIIC / Australia Non-Industrial Use	Yes		
Canada - DSL	Yes		
Canada - NDSL	No (Celite; cristobalite; 2,6-di-tert-butyl-4-methylphenol*; Silanamine, 1,1,1-trimethyl-N- (trimethylsilyl)-, hydrolysis products with silica)		
China - IECSC	Yes		
Europe - EINEC / ELINCS / NLP	Yes		
Japan - ENCS	No (Celite; Silanamine, 1,1,1-trimethyl-N- (trimethylsilyl)-, hydrolysis products with silica)		
Korea - KECI	Yes		
New Zealand - NZIoC	Yes		
Philippines - PICCS	Yes		
USA - TSCA	All chemical substances in this product have been designated as TSCA Inventory 'Active'		
Taiwan - TCSI	Yes		
Mexico - INSQ	No (Silanamine, 1,1,1-trimethyl-N- (trimethylsilyl)-, hydrolysis products with silica)		
Vietnam - NCI	Yes		
Russia - FBEPH	No (Silanamine, 1,1,1-trimethyl-N- (trimethylsilyl)-, hydrolysis products with silica)		
Legend:	Yes = All CAS declared ingredients are on the inventory No = One or more of the CAS listed ingredients are not on the inventory. These ingredients may be exempt or will require registration.		

SECTION 16 Other information

Revision Date	10/09/2024
Initial Date	17/12/2021

Full text Risk and Hazard codes

H373	May cause damage to organs through prolonged or repeated exposure.
------	--

H410	Very toxic to aquatic life with long lasting effects.

SDS Version Summary

Version	Date of Update	Sections Updated
2.3	10/09/2024	Toxicological information - Acute Health (inhaled), Toxicological information - Acute Health (skin), Toxicological information - Chronic Health, Hazards identification - Classification, Disposal considerations - Disposal, Ecological Information - Environmental, Exposure controls / personal protection - Exposure Standard, Firefighting measures - Fire Fighter (fire fighting), Composition / information on ingredients - Ingredients, Exposure controls / personal protection - Personal Protection (Respirator), Handling and storage - Storage (storage incompatibility)

Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

For detailed advice on Personal Protective Equipment, refer to the following EU CEN Standards:

EN 166 Personal eye-protection

EN 340 Protective clothing

EN 374 Protective gloves against chemicals and micro-organisms

EN 13832 Footwear protecting against chemicals

EN 133 Respiratory protective devices

Definitions and abbreviations

- PC TWA: Permissible Concentration-Time Weighted Average
- ▶ PC STEL: Permissible Concentration-Short Term Exposure Limit
- ► IARC: International Agency for Research on Cancer
- ▶ ACGIH: American Conference of Governmental Industrial Hygienists
- ▶ STEL: Short Term Exposure Limit
- ► TEEL: Temporary Emergency Exposure Limit。
- ▶ IDLH: Immediately Dangerous to Life or Health Concentrations
- ▶ ES: Exposure Standard
- ▶ OSF: Odour Safety Factor
- NOAEL: No Observed Adverse Effect Level
- ▶ LOAEL: Lowest Observed Adverse Effect Level
- ► TLV: Threshold Limit Value
- ▶ LOD: Limit Of Detection
- OTV: Odour Threshold Value
- ▶ BCF: BioConcentration Factors
- ▶ BEI: Biological Exposure Index
- ▶ DNEL: Derived No-Effect Level
- ▶ PNEC: Predicted no-effect concentration
- ▶ MARPOL: International Convention for the Prevention of Pollution from Ships
- ► IMSBC: International Maritime Solid Bulk Cargoes Code
- IGC: International Gas Carrier Code
- ▶ IBC: International Bulk Chemical Code
- AIIC: Australian Inventory of Industrial Chemicals
- ▶ DSL: Domestic Substances List
- ▶ NDSL: Non-Domestic Substances List
- ▶ IECSC: Inventory of Existing Chemical Substance in China
- ▶ EINECS: European INventory of Existing Commercial chemical Substances
- ▶ ELINCS: European List of Notified Chemical Substances
- ▶ NLP: No-Longer Polymers
- ▶ ENCS: Existing and New Chemical Substances Inventory
- ▶ KECI: Korea Existing Chemicals Inventory
- ▶ NZIoC: New Zealand Inventory of Chemicals
- ▶ PICCS: Philippine Inventory of Chemicals and Chemical Substances
- TSCA: Toxic Substances Control Act
- ▶ TCSI: Taiwan Chemical Substance Inventory
- ▶ INSQ: Inventario Nacional de Sustancias Químicas
- NCI: National Chemical Inventory
- ▶ FBEPH: Russian Register of Potentially Hazardous Chemical and Biological Substances

Page **16** of **16** Issue Date: 10/09/2024 Version No: 3.3 Print Date: 19/11/2024

AFFINIS Black Edition heavy body

Classification according to regulation (EC) No 1272/2008 [CLP] and amendments	Classification Procedure
, EUH210	Calculation method

Powered by AuthorITe, from Chemwatch.